Global Hematology (CBC) Analyzers Market, By Products and Services (Hematology Products and Services, Hemostasis Products and Services, Immunohematology Products and Services), Price Range (High-End, Mid-Range, Low-End), End-User (Hospital Laboratories, Commercial Service Providers, Government Reference Laboratories, Research, Academic Institutes) – Industry Trends and Forecast to 2030.
Hematology (CBC) Analyzers Market Analysis and Size
The market for hematology analyzers and reagents is likely driven by the rates for automated hematology instruments and the preferences for high-sensitivity point-of-care (POC) hematology tests. Rapid technology advancements, such as applying fundamental flow cytometry techniques and the expansion of high throughput hematology analyzers, are also projected to impact the industry's drivers significantly.
Data Bridge Market Research analyzes that the hematology (CBC) analyzers market which was USD 5.31 billion in 2022, is likely to reach USD 6.57 billion by 2030, and is expected to undergo a CAGR of 4.2% during the forecast period. “Hematology products and services” dominates the products and services segment of the hematology (CBC) analyzers market due to the growing demand for hematology products for chronic disease diagnosis. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015-2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, and Pricing in USD
|
|
Segments Covered
|
Products and Services (Hematology Products and Services, Hemostasis Products and Services, Immunohematology Products and Services), Price Range (High-End, Mid-Range, Low-End), End-User (Hospital Laboratories, Commercial Service Providers, Government Reference Laboratories, Research, Academic Institutes)
|
|
Countries Covered
|
U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, U.A.E., Egypt, Israel, Rest of Middle East & Africa
|
|
Market Players Covered
|
Abbott. (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Sysmex Asia Pacific Pte. Ltd (Japan), Beckman Coulter, Inc. (U.S.), Siemens Healthcare GmbH (Germany), Bayer AG (Germany), HORIBA (Japan), Boule (Sweden), Bio-Rad Laboratories, Inc. (U.S.), Nihon Kohden Corporation (Japan), Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (China), BioSystems (Spain), Diatron (Hungary), Drew Scientific (U.S.), EKF Diagnostics (U.K.), Ortho Clinical Diagnostics (U.S.), Medonic (a subsidiary of Boule Diagnostics AB) (Sweden), Heska Corporation (U.S.), Perlong Medical Equipment Co., Ltd. (China) and Shenzhen Landwind Industry Co., Ltd. (China)
|
|
Market Opportunities
|
|
Market Definition
Hematology analyzers are medical instruments that classify and count the number of blood cells in a patient's blood sample. Differential white blood cell counts are also analyzed using this equipment. The features of hematology analyzers vary according to the different medical equipment, and users can specify which testing service or analysis they require depending on these features.
Global Hematology (CBC) Analyzers Market Dynamics
Drivers
- Increasing prevalence of blood disorders
The growing incidence of blood disorders such as anemia, leukemia, and hemophilia drives the demand for hematology analyzers. These analyzers play a crucial role in the diagnosis, monitoring, and management of blood-related conditions.
- Growing demand for point-of-care testing
There is a rising demand for point-of-care hematology analyzers, particularly in remote and underserved areas where access to centralized laboratories may be limited. Point-of-care analyzers enable rapid testing and on-site diagnosis, facilitating timely treatment decisions.
- Aging population and chronic diseases
The global aging population is prone to various chronic diseases that require regular blood monitoring. As the elderly population increases, the demand for hematology analyzers rises, as they are essential tools for the diagnosis and management of conditions such as cancer, cardiovascular diseases, and autoimmune disorders.
- Growing investment in healthcare facilities
Surging focus on improving the condition of healthcare facilities and improving the overall healthcare infrastructure another important factor fostering the growth of the market. Rising number of partnerships and strategic collaborations between the public and private players pertaining to funding and application of new and improved technology is further creating lucrative market opportunities.
Opportunities
- Integration of artificial intelligence (AI) and machine learning (ML)
Integrating AI and ML technologies into hematology analyzers presents an opportunity for enhanced diagnostic accuracy and efficiency. AI algorithms can assist in identifying and classifying blood cells, analyzing complex patterns, and providing more precise and automated interpretations of test results. The development of AI-driven hematology analyzers holds the potential to revolutionize blood diagnostics and improve patient care.
- Personalized medicine and companion diagnostics
The growing focus on personalized medicine and targeted therapies creates an opportunity for the hematology analyzers market. Hematology analyzers can play a vital role in companion diagnostics, which involves identifying specific biomarkers to determine patient response to particular treatments. As personalized medicine continues to advance, the demand for hematology analyzers capable of delivering tailored diagnostic information is expected to increase.
Restraints/Challenges
- High cost of hematology analyzers
Hematology analyzers can be costly to purchase and maintain, especially the advanced models with additional features and automation capabilities. The high cost can pose a significant barrier to adoption, particularly for smaller healthcare facilities and laboratories with limited budgets. Cost considerations can limit the market growth, especially in resource-constrained settings.
- Stringent regulatory requirements
Hematology analyzers are medical devices subject to strict regulatory standards and approvals. The process of obtaining regulatory clearances or certifications can be time-consuming and expensive. Stringent regulations, including compliance with quality standards and clinical validation, can create barriers for new entrants and hinder market growth.
- Interference from other diagnostic technologies
Hematology analyzers face competition from alternative diagnostic technologies such as flow cytometry, molecular diagnostics, and point-of-care testing devices. These technologies offer specific advantages and applications, and their growing adoption can pose challenges to the hematology analyzer market. Manufacturers need to demonstrate the unique benefits and cost-effectiveness of hematology analyzers compared to alternative diagnostic methods.
- Sample preparation and pre-analytical variability
Hematology analyzers require appropriate sample preparation, including handling and processing of blood samples, to obtain accurate and reliable results. Pre-analytical variability, such as improper sample collection, transportation, and storage, can affect the quality of results and lead to inaccuracies. Standardizing sample preparation procedures and addressing pre-analytical challenges pose ongoing challenges for the market.
This hematology (CBC) analyzers market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the hematology (CBC) analyzers market contact Data Bridge Market Research for an analyst brief, our team will help you make an informed market decision to achieve market growth.
Recent Developments
- In May 2022, Nihon Kohden India established a new hematology analyzer reagent factory
- In March 2022, Mindray launched the BC-700 Series, a revolutionary hematology analyzer series that includes both complete blood count (CBC) and erythrocyte sedimentation rate (ESR) tests
Global Hematology (CBC) Analyzers Market Scope
The hematology (CBC) analyzers market is segmented on the basis of product and services, price range, and end-user. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Products and Services
- Hematology Products and Services
- Hemostasis Products and Services
- Immunohematology Products and Services
Price Range
- High-End
- Mid-Range
- Low-End
End-User
- Hospital Laboratories
- Commercial Service Providers
- Government Reference Laboratories
- Research and Academic Institutes
Global Hematology (CBC) Analyzers Market Regional Analysis/Insights
The global hematology (CBC) analyzers market is analysed and market size insights and trends are provided by country, product and services, price range, and end-user as referenced above.
The countries covered in the hematology (CBC) analyzers market report are U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, rest of Asia-Pacific, Brazil, Argentina, rest of South America, South Africa, Saudi Arabia, U.A.E., Egypt, Israel, rest of Middle East & Africa.
North America is expected to dominate the hematology (CBC) analyzers market due to the strong base of healthcare facilities, the strong existence of major players in the market increases cases of surgical procedures among athletes, and increasing number of research activities in this region.
Asia-Pacific is expected to witness significant growth during the forecast period of 2023 to 2030 due to the rising adoption rates of automated hematology instruments and rising desires for high sensitivity point-of-care (POC) hematology testing.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends, and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of domestic tariffs, and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure Growth Installed Base and New Technology Penetration
The hematology (CBC) analyzers market also provides you with a detailed market analysis for every country's growth in healthcare expenditure for capital equipment, installed base of different kinds of products for the hematology (CBC) analyzers market, the impact of technology using lifeline curves and changes in healthcare regulatory scenarios and their impact on the hematology (CBC) analyzers market.
Competitive Landscape and Hematology (CBC) Analyzers Market Share Analysis
The hematology (CBC) analyzers market competitive landscape provides details by competitors. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width, and breadth, application dominance. The above data points provided are only related to the companies' focus related to the hematology (CBC) analyzers market.
Some of the major players operating in the hematology (CBC) analyzers market are:
- Abbott. (U.S.)
- F. Hoffmann-La Roche Ltd (Switzerland)
- Sysmex Asia Pacific Pte. Ltd (Japan)
- Beckman Coulter, Inc. (U.S.)
- Siemens Healthcare GmbH (Germany)
- Bayer AG (Germany)
- HORIBA (Japan)
- Boule (Sweden)
- Bio-Rad Laboratories, Inc. (U.S.)
- Nihon Kohden Corporation (Japan)
- Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (China)
- BioSystems (Spain)
- Diatron (Hungary)
- Drew Scientific (U.S.)
- EKF Diagnostics (U.K.)
- Ortho Clinical Diagnostics (U.S.)
- Medonic (a subsidiary of Boule Diagnostics AB) (Sweden)
- Heska Corporation (U.S.)
- Perlong Medical Equipment Co., Ltd. (China)
- Shenzhen Landwind Industry Co., Ltd. (China)
SKU-